Anika E. Adeni

1.7k total citations
19 papers, 635 citations indexed

About

Anika E. Adeni is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Cancer Research. According to data from OpenAlex, Anika E. Adeni has authored 19 papers receiving a total of 635 indexed citations (citations by other indexed papers that have themselves been cited), including 18 papers in Oncology, 15 papers in Pulmonary and Respiratory Medicine and 4 papers in Cancer Research. Recurrent topics in Anika E. Adeni's work include Cancer Immunotherapy and Biomarkers (16 papers), Lung Cancer Treatments and Mutations (11 papers) and Lung Cancer Diagnosis and Treatment (4 papers). Anika E. Adeni is often cited by papers focused on Cancer Immunotherapy and Biomarkers (16 papers), Lung Cancer Treatments and Mutations (11 papers) and Lung Cancer Diagnosis and Treatment (4 papers). Anika E. Adeni collaborates with scholars based in United States, Spain and Italy. Anika E. Adeni's co-authors include Mark M. Awad, Mizuki Nishino, Biagio Ricciuti, Suzanne E. Dahlberg, Lynette M. Sholl, Pasi A. Jänne, F. Stephen Hodi, Hiroto Hatabu, Christine Lydon and Emily S. Chambers and has published in prestigious journals such as Journal of Clinical Oncology, Cancer Research and Clinical Cancer Research.

In The Last Decade

Anika E. Adeni

18 papers receiving 632 citations

Peers

Anika E. Adeni
Yosuke Kawashima Japan
Krikor Bornazyan United States
Kuninobu Kanai Japan
Lauren Xu United States
Walter Quan United States
Lucía Teijeira Spain
Rie Sakakibara Japan
Robert S. Brody United States
Juan I. Pascual Spain
Yarne Klaver Netherlands
Yosuke Kawashima Japan
Anika E. Adeni
Citations per year, relative to Anika E. Adeni Anika E. Adeni (= 1×) peers Yosuke Kawashima

Countries citing papers authored by Anika E. Adeni

Since Specialization
Citations

This map shows the geographic impact of Anika E. Adeni's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Anika E. Adeni with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Anika E. Adeni more than expected).

Fields of papers citing papers by Anika E. Adeni

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Anika E. Adeni. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Anika E. Adeni. The network helps show where Anika E. Adeni may publish in the future.

Co-authorship network of co-authors of Anika E. Adeni

This figure shows the co-authorship network connecting the top 25 collaborators of Anika E. Adeni. A scholar is included among the top collaborators of Anika E. Adeni based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Anika E. Adeni. Anika E. Adeni is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

19 of 19 papers shown
1.
Ogino, Atsuko, Jihyun Choi, Margaret K. Wilkens, et al.. (2020). Genomic and pathological heterogeneity in clinically diagnosed small cell lung cancer in never/light smokers identifies therapeutically targetable alterations. Molecular Oncology. 15(1). 27–42. 16 indexed citations
2.
Keegan, Alissa, Biagio Ricciuti, Padric M. Garden, et al.. (2020). Plasma IL-6 changes correlate to PD-1 inhibitor responses in NSCLC. Journal for ImmunoTherapy of Cancer. 8(2). e000678–e000678. 108 indexed citations
3.
Ricciuti, Biagio, Greg Jones, Anika E. Adeni, et al.. (2020). Early plasma circulating tumor DNA (ctDNA) changes to predict response to first-line pembrolizumab +/- chemotherapy in non-small cell lung cancer (NSCLC).. Journal of Clinical Oncology. 38(15_suppl). 3518–3518. 2 indexed citations
4.
Alessandrino, Francesco, Sonia Sahu, Mizuki Nishino, et al.. (2019). Frequency and imaging features of abdominal immune-related adverse events in metastatic lung cancer patients treated with PD-1 inhibitor. Abdominal Radiology. 44(5). 1917–1927. 33 indexed citations
5.
Aguilar, Elizabeth Jiménez, Biagio Ricciuti, Justin F. Gainor, et al.. (2019). Outcomes to first-line pembrolizumab in patients with non-small cell lung cancer and a PD-L1 tumor proportion score ≥90%.. Journal of Clinical Oncology. 37(15_suppl). 9111–9111. 2 indexed citations
6.
Ricciuti, Biagio, Suzanne E. Dahlberg, Anika E. Adeni, et al.. (2019). Immune Checkpoint Inhibitor Outcomes for Patients With Non–Small-Cell Lung Cancer Receiving Baseline Corticosteroids for Palliative Versus Nonpalliative Indications. Journal of Clinical Oncology. 37(22). 1927–1934. 201 indexed citations
7.
Vokes, Natalie I., Renato Umeton, Anika E. Adeni, et al.. (2019). Abstract 2514: Inter-test variability in tumor mutational burden (TMB) quantification and identification of TMB thresholds. Cancer Research. 79(13_Supplement). 2514–2514. 1 indexed citations
8.
Vokes, Natalie I., Anika E. Adeni, Renato Umeton, et al.. (2018). MA19.01 Efficacy and Genomic Correlates of Response to Anti-PD1/PD-L1 Blockade in Non-Small Cell Lung Cancers Harboring Targetable Oncogenes. Journal of Thoracic Oncology. 13(10). S422–S422. 9 indexed citations
9.
Gainor, Justin F., Sasha Kravets, S. Khosrowjerdi, et al.. (2018). MA04.05 Outcomes in NSCLC Patients Treated with First-Line Pembrolizumab and a PD-L1 TPS of 50-74% vs 75-100% or 50-89% vs 90-100%. Journal of Thoracic Oncology. 13(10). S367–S368. 9 indexed citations
10.
Leonardi, Giulia C., Anika E. Adeni, Christine Lydon, et al.. (2018). Safety and Efficacy of PD-1 Inhibitors Among HIV-Positive Patients With Non–Small Cell Lung Cancer. Journal of Thoracic Oncology. 13(7). 1037–1042. 69 indexed citations
11.
Aguilar, Elizabeth Jiménez, Hira Rizvi, Sasha Kravets, et al.. (2018). Comparison of outcomes with PD-L1 tumor proportion score (TPS) of 50-74% vs 75-100% in patients with non-small cell lung cancer (NSCLC) treated with first-line PD-1 inhibitors.. Journal of Clinical Oncology. 36(15_suppl). 9037–9037. 7 indexed citations
12.
Mahadevan, Navin R., Anika E. Adeni, Peter S. Hammerman, et al.. (2017). MA15.02 Non-Synonymous Mutation Burden in Lung Carcinoma is Associated with Durable Clinical Response to Immune Checkpoint Blockade. Journal of Thoracic Oncology. 12(1). S428–S429. 3 indexed citations
13.
Nishino, Mizuki, Anika E. Adeni, Hiroto Hatabu, et al.. (2017). P2.07-002 Drug-Related Pneumonitis in Advanced Non-Small-Cell Lung Cancer (NSCLC) Patients Treated with Commercial PD-1 Inhibitors. Journal of Thoracic Oncology. 12(11). S2416–S2416.
14.
Nishino, Mizuki, et al.. (2017). P1.01-055 Spectrum of Early Progression in Advanced NSCLC Patients Treated with PD-1 Inhibitors: Identifying Markers for Poor Outcome. Journal of Thoracic Oncology. 12(11). S1915–S1916. 1 indexed citations
15.
Nishino, Mizuki, Suzanne E. Dahlberg, Anika E. Adeni, et al.. (2017). Tumor response dynamics of advanced non-small-cell lung cancer (NSCLC) patients (pts) treated with commercial PD-1 inhibitors in the clinical setting.. Journal of Clinical Oncology. 35(15_suppl). 9087–9087. 1 indexed citations
16.
Nishino, Mizuki, Suzanne E. Dahlberg, Anika E. Adeni, et al.. (2017). Tumor Response Dynamics of Advanced Non–small Cell Lung Cancer Patients Treated with PD-1 Inhibitors: Imaging Markers for Treatment Outcome. Clinical Cancer Research. 23(19). 5737–5744. 57 indexed citations
17.
Awad, Mark M., Cristina Mastini, Rafael B. Blasco, et al.. (2017). Epitope mapping of spontaneous autoantibodies to anaplastic lymphoma kinase (ALK) in non-small cell lung cancer. Oncotarget. 8(54). 92265–92274. 18 indexed citations
18.
Nishino, Mizuki, Nikhil H. Ramaiya, Emily S. Chambers, et al.. (2016). Immune-related response assessment during PD-1 inhibitor therapy in advanced non-small-cell lung cancer patients. Journal for ImmunoTherapy of Cancer. 4(1). 84–84. 96 indexed citations
19.
Conroy, Thierry, et al.. (2006). [Recommendations for clinical practice: management with first-line palliative chemotherapy for patients with metastatic colorectal cancer].. PubMed. 93(2). 197–200. 2 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Yosuke Kawashima Breakdown of academic impact, for papers by Krikor Bornazyan Breakdown of academic impact, for papers by Kuninobu Kanai Breakdown of academic impact, for papers by Lauren Xu Breakdown of academic impact, for papers by Walter Quan Breakdown of academic impact, for papers by Lucía Teijeira Breakdown of academic impact, for papers by Rie Sakakibara Breakdown of academic impact, for papers by Robert S. Brody Breakdown of academic impact, for papers by Juan I. Pascual Breakdown of academic impact, for papers by Yarne Klaver
Rankless by CCL
2026